Oct 14 (Reuters) - UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals
in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.
Vanda in June rejected takeover offers from Cycle Pharma and a revised bid from contract manufacturer Future Pak.
WHY IT'S IMPORTANT Cycle has proposed to acquire Vanda for $8 per share, an 80% premium to Vanda's last closing price. The potential offer follows a 4.5% decline in Vanda's shares after the U.S Food and Drug Administration declined to approve its drug for a stomach condition that disrupts digestion.
CONTEXT Vanda in April adopted a shareholder rights plan, known as a "poison pill", to reduce the likelihood of a hostile takeover.
Vanda has three approved products, sleep disorder treatment Hetlioz, Fanapt for bipolar I disorder and Ponvory to treat multiple sclerosis.
KEY QUOTE "We stand ready to work immediately with Vanda's board and management team to reach an agreement that would provide a compelling premium and certain cash value today for all Vanda shareholders," Cycle Pharma said in a statement.
Vanda did not immediately respond to a Reuters request for comment.
MARKET REACTION Shares of Vanda are up 12.3% at $4.99.
(Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.